arrow
J

Jean Addington

University of Calgary
H指数:89
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unraveling Suicidal Ideation and Behaviors in a Global Cohort of Individuals at Clinical High-Risk for Psychosis: Multivariable Correlates and Subthreshold Psychotic Symptoms

揭示全球临床高风险精神分裂症个体中的自杀意念与行为:多变量相关因素和阈下精神病症状

2026-09-130
OAAI
Association Between Social and Role Functioning and Transition to Psychosis in the North American Prodrome Longitudinal Study Consortium

社会与角色功能与精神病发作之间的关系:北美前驱期纵向研究联盟的研究

2026-08-110
OAAI
Processing Speed and Verbal Learning Ability as Predictors of Assessor-Rated and Ecological Momentary Assessment Self-Reported Functioning: Findings from AMP SCZ

处理速度和言语学习能力作为评估者评定和生态瞬时评估自报功能表现的预测因素:AMP SCZ的研究发现

2026-08-030
PRE
Correlation networks of blood proteins in the neuroimmunology of schizophrenia—replication and extension

精神分裂症神经免疫学中血液蛋白质的相关网络——重复与扩展

2026-04-110
OAAI
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative

收集语言、语音声学和面部表情数据以预测精神分裂症及其他临床结果:AMP® SCZ倡议的策略

2025-10-150
OAAI
Shift in sex and age of individuals at a clinical high risk (CHR) for psychosis: relation to differences in recruitment methods and effect on sample characteristics

精神病临床高风险(CHR)个体在性别和年龄上的变化:与招募方法差异的关系及其对样本特征的影响

2025-10-060
OAAI
Exploring the pathways between early auditory processing, processing speed, social cognition, and negative symptoms on social functioning in individuals at clinical high risk for psychosis: A structural equation modeling approach

探讨早期听觉处理、处理速度、社会认知和阴性症状对精神疾病临床高风险个体社会功能的影响路径:一项结构方程模型研究

2025-07-070
PRE
Cognitive subtypes in youth at clinical high risk for psychosis

精神分裂症临床高风险青少年的认知亚型

2025-07-020
PRE
High rates of suicidality and parasuicidal behavior in individuals at clinical high-risk for psychosis: Implications for suicide risk assessment and suicide prevention

精神病临床高风险个体中自杀意念和准自杀行为的超高发生率:对自杀风险评估和自杀预防的启示

2025-07-010
PRE
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

加速药品合作计划®精神分裂症项目中的脑电图协议:测量指标的可靠性与稳定性

2025-06-060
OAAI
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

加速药物合作®精神分裂症计划中的数字健康技术

2025-06-030
OAAI
Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program

加速药物伙伴关系®精神分裂症计划的数据分析策略

2025-04-031
OA
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program

样本确定和临床结局指标在加速药物伙伴关系®精神分裂症计划中

2025-04-031
OA
Neighborhood social fragmentation in relation to impaired mismatch negativity among youth at clinical high risk for psychosis and healthy comparisons

在精神病和健康比较的临床高风险中,与青少年的不匹配负相关性受损有关的邻里社会分裂

2025-04-010
PRE
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

加速药物伙伴关系中的认知评估®精神分裂症计划: 在不同的国际样本中协调优先事项和策略

2025-03-240
OAAI
Emergence and Dynamics of Delusions and Hallucinations Across Stages in Early Psychosis

早期精神分裂症各阶段妄想和幻觉的出现与发展动态

2025-02-260
OA